Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.
about
TPO receptor agonist for chronic idiopathic thrombocytopenic purpuraAdvances in Diagnosis and Treatments for Immune ThrombocytopeniaFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsSevere bleeding events in adults and children with primary immune thrombocytopenia: a systematic reviewContemporary management of primary immune thrombocytopenia in adultsDrugs derived from phage display: from candidate identification to clinical practiceChildhood immune thrombocytopenia: Clinical presentation and managementBeyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.Romiplostim management of immune thrombocytopenic purpura.Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.Treatment of immune thrombocytopenic purpura: focus on eltrombopag.New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.Assessment of immunogenicity of romiplostim in clinical studies with ITP subjectsF104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents.Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis.Long-term management of chronic immune thrombocytopenic purpura in adults.Current status of thrombopoietic agents.Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters.Pathophysiology and therapeutic options in primary immune thrombocytopenia.Romiplostim in children with chronic refractory ITP: randomized placebo controlled study.Current treatment options for primary immune thrombocytopenia.Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.The development of romiplostim for patients with immune thrombocytopenia.ITP: a historical perspective.What's new in the management of chronic primary immune thrombocytopenia in adults and the use of thrombopoietin receptor agonists.Eltrombopag for the treatment of immune thrombocytopenia.Management of immune thrombocytopenic purpura in children: potential role of novel agents.Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.The role of platelet factor 4 in radiation-induced thrombocytopeniaThrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities.Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim.Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP).Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia.Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.Romiplostim: a review of its use in immune thrombocytopenia.Successful treatment with thrombopoietin receptor agonist in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia
P2860
Q24235481-E7425474-8E8C-4561-A935-43776DF3D2C2Q26738630-5E7D22CD-827D-4751-8DD0-85F69AFA8032Q26822421-4D55C5DE-4841-48AC-B644-683C725670BFQ26826853-AD7A27E1-50F8-41EC-8B4A-05CF9A32CD0BQ26853680-3A797939-8B96-4FB5-BEB0-DC8A7F75D9A7Q27007101-23BDB814-C7D4-418C-8AD4-14C89A81FE0EQ27023294-7F708F0B-BAA1-4ADC-9156-2BC88C429648Q30399669-18FBDDF0-6A01-485E-AB9F-AC9FD357A58EQ31089024-6B274BE6-89F7-44C1-95F5-D9C393FD33D3Q33384267-57C8A89F-EE1C-43E0-81FE-4358C6179A8AQ33384996-5972FC34-8204-43C0-9CBF-69FDE2F9C42BQ33385976-39028F4B-BB8A-4772-9993-D1F0CCB7CBD4Q33387735-7BFE713D-34AF-4CE1-8DAF-452AD9BE84FCQ33388267-4F84DFAA-BE03-499B-8408-0C895DEA8DE7Q33388407-04EFB28B-C133-4BF7-9FC5-972DE9C90A2FQ33390380-D9B87889-F82E-43A8-A2BE-686C55B96DDAQ33391221-1EF0F053-DBD8-43CD-810C-E1A1217D04AFQ33392179-161AF1E0-F9AB-4A83-9DE0-B8BD953D9DEDQ33392610-39E0F573-2D10-4019-B07B-BE5078ABD249Q33392858-6052750D-42D3-4CB6-8CD3-CDDD79F0A519Q33392868-2C7A4AD2-7F92-40E7-996A-5F4510DE4665Q33393732-9F864872-E70E-4462-B10B-F24A9BED7C98Q33394122-42E406F4-B577-4B63-A738-8634F5BBCAABQ33394149-CA6A2521-45F1-42DF-8E8D-88C154726C3DQ33394296-C88B3F01-281E-4605-856B-577378C60666Q33394636-F3372AB8-6116-43D2-8779-AC5191439ACEQ33394791-D05D35A0-7FE0-46ED-A25A-D66B4E9A54E0Q33395345-BAED93F6-D542-47FD-AB84-A244A46E1390Q33395776-47E957C9-A8F4-47D7-91BB-99B18195CDACQ33395863-86B5CC97-48E5-4132-8D15-0F85F0A9967FQ33395943-527D052A-CC5F-4451-AC67-E37C7FB7176AQ33396167-0D68B7B3-AB95-4488-8FA0-413A00BBFDC3Q33396730-2D5189BA-41F8-42DA-979A-7AE0DBED4288Q33397092-4E8F6469-2F4F-4442-B34A-AABFF2DF636BQ33397101-7D81108A-5C1B-4696-B6FB-FBB144F9590CQ33397133-6ED30709-1A58-464D-BB87-6A640C755279Q33398217-8A3C4672-D853-4A41-B1CE-9BB79E5573FFQ33398815-06ED948E-3300-4F19-BDCA-68F30F98B951Q33399598-1AE43B5D-6C40-48B4-96D1-236F95039E26Q33399821-F27FB823-CE89-46E9-B00E-9D05AFF93BF1
P2860
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Safety and efficacy of long-te ...... nic patients with chronic ITP.
@ast
Safety and efficacy of long-te ...... nic patients with chronic ITP.
@en
type
label
Safety and efficacy of long-te ...... nic patients with chronic ITP.
@ast
Safety and efficacy of long-te ...... nic patients with chronic ITP.
@en
prefLabel
Safety and efficacy of long-te ...... nic patients with chronic ITP.
@ast
Safety and efficacy of long-te ...... nic patients with chronic ITP.
@en
P2093
P1433
P1476
Safety and efficacy of long-te ...... nic patients with chronic ITP.
@en
P2093
David J Kuter
Janet L Nichol
Matthew Guo
Roger M Lyons
Vinod Pullarkat
P304
P356
10.1182/BLOOD-2008-04-150078
P407
P577
2008-11-03T00:00:00Z